Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | CCR1 | P32246 | 7/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832785 | 0.87 | MAPK1 (0.71) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL1420155 | 0.87 | KMT2A (0.61) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL7510664 | 0.86 | KMT2A (0.56) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL3517559 | 0.85 | MAPK1 (0.73) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL15167344 | 0.83 | GPR35 (0.56) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL20647185 | 0.83 | KMT2A (0.54) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5676678 | 0.82 | RAB9A (0.43) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL6052216 | 0.82 | CCR1 (0.51) | KMT2AMEN1NPC1RAB9AMAPK1 | |
| SCHEMBL13832772 | 0.82 | KMT2A (0.53) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5680536 | 0.81 | PTGS2 (0.46) | KMT2AMEN1NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297112-B1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-04-03 | — | — | EP | disclosed |
| EP-2297112-B1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2297112-A1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009137338-A1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| EP-1620405-A2 | PYRAZOLE-AMIDES AND SULFONAMIDES AS SODIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2006-02-01 | — | — | EP | disclosed |
| CN-1230421-C | Amide compound and pharmaceutical use thereof | MITSUBISHI CHEM CORP (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-6969713-B2 | Piperidine and piperazine acetamide derivatives | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| US-20050020564-A1 | Pyrazole-amides and sulfonamides as sodium channel modulators | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004099154-A2 | PYRAZOLE-AMIDES AND SULFONAMIDES AS SODIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040220170-A1 | Pyrazole-amides and sulfonamides as sodium channel modulators | ABBOTT LABORATORIES | 2004-11-04 | — | — | US | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| CN-1346348-A | Amide compound and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2002-04-24 | — | — | CN | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | KMT2A 2632/4885MEN1 4195/4885NPC1 87/4885 |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | CCR1, CCR3, CCR4 | KMT2A 4717/4885MEN1 3153/4885NPC1 1189/4885 |
| US-20050020564-A1 | Pyrazole-amides and sulfonamides as sodium channel modulators | SCN3A, KCNN3, TRPV3 | KMT2A 2788/4885MEN1 4304/4885NPC1 4129/4885 |
| US-20040220170-A1 | Pyrazole-amides and sulfonamides as sodium channel modulators | SCN3A, KCNN3, TRPV3 | KMT2A 2788/4885MEN1 4304/4885NPC1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.